Immix Biopharma (IMMX) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on chimeric antigen receptor cell therapy (CAR-T) for AL Amyloidosis and other serious diseases.

• Lead candidate NXC-201 is FDA IND-cleared, in Phase 1b/2 clinical trial, and has received RMAT and Orphan Drug Designation from FDA and EMA.

• Strategy centers on developing NXC-201 for AL Amyloidosis and expanding into other indications where CAR-T is not yet approved.

Financial performance and metrics

• Recent PIPE transaction in September 2025 raised gross proceeds of approximately $9.3 million, before fees and expenses.

• Warrants issued in the PIPE have an exercise price of $2.00 per share and could generate up to $5.87 million in additional gross proceeds if fully exercised in cash.

Use of proceeds and capital allocation

• Proceeds from any cash exercise of the Warrants will be used for working capital and general corporate purposes; management has broad discretion over timing and application.

• No proceeds will be received from the resale of shares by selling stockholders.